1
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, suite B
New Haven, CT 06511
1 of 3
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecologic OncologyPark Avenue Medical Center5520 Park Avenue, Ste 1-500Trumbull, CT 06611
Masoud Azodi, MD
Minimally Invasive Surgery, Gynecologic Oncology, Obstetrics, Gynecology & Reproductive Sciences
Telehealth is available
Patient type treated
Child, Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Gynecologic Oncology and Obstetrics & Gynecology
Biography
Masoud Azodi, MD, is the director of minimally invasive and robotic surgery for Yale Medicine obstetrics, gynecology and reproductive sciences. He has a special interest in using minimally invasive surgical techniques, particularly robotic surgery to treat patients with gynecologic precancers and cancers. Dr. Azodi has been a gynecologist at Yale for more than 20 years, performing more than 3,000 conventional laparoscopic and more than 3,000 robotic-assisted surgeries for management of gynecologic diseases.
“We provide excellent patient care, and our team works with the most up-to-date surgical techniques and research,” he says. Dr. Azodi has been recognized as one of the Top Doctors in the state by Castle Connolly Medical Ltd.
In addition to practicing surgery, Dr. Azodi is a principal investigator and co-principal investigator in multiple protocols treating gynecologic cancer. He is a professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine.
Titles
- Professor of Obstetrics, Gynecology and Reproductive Sciences
- Director of Minimally Invasive and Robotic Surgery, Director of Minimally Invasive Gynecologic Surgery Fellowship
Education & Training
- FellowshipYale University School of Medicine (1999)
- ResidencyAultman Hospital/Neoucom (1996)
- MDWright State University (1992)
Languages Spoken
- English
- فارسی (Persian)
Additional Information
Board Certifications
- AB of Obstetrics & Gynecology, Gynecologic Oncology (2002, recertified: 2022)
- AB of Obstetrics & Gynecology, Obstetrics & Gynecology (2000, recertified: 2022)
Publications
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.
- Khadraoui W, Tierney C, Chung S, Mutlu L, Lu L, Azodi M, Ratner E, Menderes G. Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer. International Journal Of Gynecology & Obstetrics 2020, 150: 385-391. PMID: 32506422, DOI: 10.1002/ijgo.13254.
- Bonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.
- Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers In Oncology 2020, 10: 118. PMID: 32117765, PMCID: PMC7028697, DOI: 10.3389/fonc.2020.00118.
- Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 2020, 11: 560-570. PMID: 32082489, PMCID: PMC7007291, DOI: 10.18632/oncotarget.27342.
- Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.
- Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.
- Benabou K, Kim S, Tierney CH, Messom JE, Kyriakides TC, Kashani SM, Silasi DA, Azodi M, Seifi F. Laparoscopic Posterior Versus Lateral Transversus Abdominis Plane Block in Gynecology. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2020, 24: e2020.00032. PMID: 32831540, PMCID: PMC7434395, DOI: 10.4293/jsls.2020.00032.
- Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.
- Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
- Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology 2019, 155: 144-150. PMID: 31434613, PMCID: PMC6788971, DOI: 10.1016/j.ygyno.2019.08.010.
- Kim S, Chung S, Azodi M, Menderes G. Uterine Artery–sparing Minimally Invasive Radical Trachelectomy: A Case Report and Review of the Literature. Journal Of Minimally Invasive Gynecology 2019, 26: 1389-1395. PMID: 31173940, DOI: 10.1016/j.jmig.2019.05.017.
- Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.
- Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology 2019, 20: 636-648. PMID: 30948273, DOI: 10.1016/s1470-2045(19)30029-4.
- Azodi M, Hesson D. Robotic Surgery: Research and Reviews is indexed in PubMed. Robotic Surgery Research And Reviews 2019, 6: 1-2. PMID: 30989084, PMCID: PMC6440532, DOI: 10.2147/rsrr.s204381.
- Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.
- Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.
- Tierney C, Chung SH, Feinberg J, Haines K, Yadav G, Azodi M, Menderes G. A Novel Approach to Combined Vaginal and Laparoscopic Gynecological Surgery. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: ejsls.2019.00006. PMID: 31097905, PMCID: PMC6464071, DOI: 10.4293/jsls.2019.00006.
- Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
- Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Menderes G, Leon-Martinez D, Azodi M. Laparoscopic Ligation of Uterine Vasculature for Fertility-Sparing Management of Postabortal Hemorrhage. Journal Of Minimally Invasive Gynecology 2018, 26: 36-37. PMID: 29609031, DOI: 10.1016/j.jmig.2018.03.020.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal Of Clinical Oncology 2018, 36: 2044-2051. PMID: 29584549, DOI: 10.1200/jco.2017.76.5966.
- Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.
- Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Gynecologic Oncology Reports 2018, 23: 28-33. PMID: 29387776, PMCID: PMC5771964, DOI: 10.1016/j.gore.2018.01.003.
- Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research 2017, 23: 5836-5845. PMID: 28679774, PMCID: PMC5626613, DOI: 10.1158/1078-0432.ccr-16-2862.
- Kim S, Hill A, Menderes G, Cross S, Azodi M, Bahtiyar MO. Minimally invasive abdominal cerclage compared to laparotomy: a comparison of surgical and obstetric outcomes. Journal Of Robotic Surgery 2017, 12: 295-301. PMID: 28721634, DOI: 10.1007/s11701-017-0726-9.
- Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.
- Menderes G, Dugan K, Klein MJ, Azodi M. Natural Orifice–Assisted Laparoscopic Meckel Diverticulectomy Incidentally Found During Para-Aortic Mass Resection. Journal Of Minimally Invasive Gynecology 2017, 25: 19-20. PMID: 28478192, DOI: 10.1016/j.jmig.2017.04.015.
- Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.
- Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology 2017, 34: 91. PMID: 28397106, PMCID: PMC5896014, DOI: 10.1007/s12032-017-0956-8.
- Deshmukh U, McAdow M, Black J, Hui P, Azodi M. Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. Gynecologic Oncology Reports 2017, 20: 54-57. PMID: 28331901, PMCID: PMC5348602, DOI: 10.1016/j.gore.2017.03.001.
- Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
- Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.
- Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.
- Hill AM, Davis KM, Clark-Donat L, Hammons LM, Azodi M, Silasi DA. The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2016, 24: 108-113. PMID: 27702701, DOI: 10.1016/j.jmig.2016.09.015.
- Gojayev A, English DP, Macer M, Azodi M. Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer. Case Reports In Obstetrics And Gynecology 2016, 2016: 8547173. PMID: 27747116, PMCID: PMC5055912, DOI: 10.1155/2016/8547173.
- Menderes G, Black JD, Azodi M. The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer. Expert Review Of Anticancer Therapy 2016, 16: 899-901. PMID: 27477495, DOI: 10.1080/14737140.2016.1219658.
- Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.
- Stahl JM, Park HS, Silasi DA, Azodi M, Damast S. Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients. Practical Radiation Oncology 2016, 6: 226-232. PMID: 27364883, DOI: 10.1016/j.prro.2015.09.015.
- Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.
- Menderes G, Vilardo N, Schwab CL, Azodi M. Incidental injury and repair of obturator nerve during laparoscopic pelvic lymphadenectomy. Gynecologic Oncology 2016, 142: 208. PMID: 27234143, DOI: 10.1016/j.ygyno.2016.05.023.
- Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.
- Zeybek B, Hill A, Menderes G, Borahay MA, Azodi M, Kilic GS. Robot-Assisted Abdominal Cerclage During Pregnancy. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2016, 20: e2016.00072. PMID: 27904309, PMCID: PMC5118107, DOI: 10.4293/jsls.2016.00072.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1641-1641. PMID: 26625219, PMCID: PMC4705897, DOI: 10.1038/bjc.2015.388.
- Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics 2015, 14: 2519-2526. PMID: 26333383, PMCID: PMC4636465, DOI: 10.1158/1535-7163.mct-15-0383.
- Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.
- Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal Of Experimental & Clinical Cancer Research 2015, 34: 123. PMID: 26474755, PMCID: PMC4609066, DOI: 10.1186/s13046-015-0241-7.
- Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA. Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? Journal Of Minimally Invasive Gynecology 2015, 22: s48-s49. PMID: 27679256, DOI: 10.1016/j.jmig.2015.08.134.
- Tower AM, Clark Donat L, Azodi M, Silasi DA. The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2015, 22: s77. PMID: 27679335, DOI: 10.1016/j.jmig.2015.08.205.
- Clark Donat L, Tower A, Clark M, Silasi DA, Azodi M. Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma. Journal Of Minimally Invasive Gynecology 2015, 22: s59. PMID: 27679285, DOI: 10.1016/j.jmig.2015.08.157.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1020-1026. PMID: 26325104, PMCID: PMC4651122, DOI: 10.1038/bjc.2015.306.
- Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer. International Journal Of Cancer 2015, 137: 2618-2629. PMID: 26060989, PMCID: PMC4573336, DOI: 10.1002/ijc.29632.
- Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.
- Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 112-117. PMID: 26260909, PMCID: PMC4587290, DOI: 10.1016/j.ygyno.2015.08.002.
- Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.
- Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology 2015, 138: 11-17. PMID: 25931171, PMCID: PMC4469551, DOI: 10.1016/j.ygyno.2015.04.027.
- Menderes G, Clark M, Tower A, Azodi M. External Iliac Vein Injury and Repair During Robotic-assisted Pelvic Lymphadenectomy. Journal Of Minimally Invasive Gynecology 2015, 22: 718. PMID: 25888352, DOI: 10.1016/j.jmig.2015.04.007.
- English D, Menderes G, Azodi M. Controlled removal of a large uterus within a bowel bag and morcellation in the bowel bag from the vagina. Gynecologic Oncology 2015, 137: 589-590. PMID: 25797081, DOI: 10.1016/j.ygyno.2015.03.014.
- Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.
- Menderes G, Clark M, Clark-Donat L, Azodi M. Robotic-assisted Abdominal Cerclage Placement During Pregnancy and Its Challenges. Journal Of Minimally Invasive Gynecology 2015, 22: 713-714. PMID: 25772022, DOI: 10.1016/j.jmig.2015.03.006.
- Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology 2015, 36: 5505-5513. PMID: 25669172, PMCID: PMC5573583, DOI: 10.1007/s13277-015-3218-4.
- Donat LC, Menderes G, Tower AM, Azodi M. A Technique for Vascular Control During Robotic-assisted Laparoscopic Myomectomy. Journal Of Minimally Invasive Gynecology 2015, 22: 543. PMID: 25680685, DOI: 10.1016/j.jmig.2015.02.003.
- Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors. Cancer 2015, 121: 1817-1826. PMID: 25649370, DOI: 10.1002/cncr.29254.
- Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.
- Clark LE, Menderes G, Tower AM, Silasi DA, Azodi M. A Simple Approach to Specimen Retrieval via Posterior Colpotomy Incision. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2015, 19: e2015.00222. PMID: 25901107, PMCID: PMC4396057, DOI: 10.4293/jsls.2014.00222.
- Menderes G, Azodi M, Schwartz P, Silasi DA. Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging. International Journal Of Gynecological Cancer 2015, 25: 160-165. PMID: 25386859, DOI: 10.1097/igc.0000000000000308.
- Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics. International Journal Of Gynecological Cancer 2014, 25: 431. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/igc.0000000000000376.
- Menderes G, Clark LE, Azodi M. Needleless Laparoscopic Abdominal Cerclage Placement. Journal Of Minimally Invasive Gynecology 2014, 22: 321. PMID: 25489676, DOI: 10.1016/j.jmig.2014.11.011.
- Menderes G, Clark LE, Azodi M. Incidental Ureteral Injury and Repair during Robotic-assisted Total Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2014, 22: 320. PMID: 25461686, DOI: 10.1016/j.jmig.2014.11.006.
- Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal Of Cancer 2014, 111: 1750-1756. PMID: 25268372, PMCID: PMC4453741, DOI: 10.1038/bjc.2014.519.
- English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2014, 121: 403-412. PMID: 25251053, PMCID: PMC4304922, DOI: 10.1002/cncr.29062.
- Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical EvidenceGruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK. Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence. Cancer Prevention Research 2014, 7: 896-905. PMID: 24950779, PMCID: PMC4154987, DOI: 10.1158/1940-6207.capr-13-0408.
- Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.
- Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.
- Pasternak MC, Black JD, Buza N, Azodi M, Gariepy A. An unexpected mass of the urachus: a case report. American Journal Of Obstetrics And Gynecology 2014, 211: e1-e3. PMID: 24912094, DOI: 10.1016/j.ajog.2014.06.011.
- English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine 2014, 3: 1256-1265. PMID: 24890382, PMCID: PMC4302675, DOI: 10.1002/cam4.274.
- Menderes G, Clark L, Azodi M. Robotic-assisted abdominal cerclage: a case report and literature review. Journal Of Robotic Surgery 2014, 8: 195-200. PMID: 27637677, DOI: 10.1007/s11701-014-0462-3.
- Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.
- Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.
- Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, Mor G. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine 2013, 2: 751-762. PMID: 24403249, PMCID: PMC3892380, DOI: 10.1002/cam4.115.
- Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British Journal Of Cancer 2013, 109: 462-471. PMID: 23807163, PMCID: PMC3721400, DOI: 10.1038/bjc.2013.315.
- Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119: 2582-2592. PMID: 23585021, PMCID: PMC3700638, DOI: 10.1002/cncr.28017.
- Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 2916-2921. PMID: 23359684, PMCID: PMC3581983, DOI: 10.1073/pnas.1222577110.
- La Rosa MF, McCarthy S, Richter C, Azodi M. Robotic Repair of Uterine Dehiscence. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2013, 17: 156-160. PMID: 23743391, PMCID: PMC3662738, DOI: 10.4293/108680812x13517013317996.
- Silasi DA, Gallo T, Silasi M, Menderes G, Azodi M. Robotic Versus Abdominal Hysterectomy for Very Large Uteri. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2013, 17: 400-406. PMID: 24018076, PMCID: PMC3771758, DOI: 10.4293/108680813x13693422521755.
- Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal Of Surgical Oncology 2012, 107: 195-200. PMID: 22648987, DOI: 10.1002/jso.23171.
- Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal Of Cancer 2012, 106: 1543-1550. PMID: 22531721, PMCID: PMC3341945, DOI: 10.1038/bjc.2012.132.
- Kashani S, Gallo T, Sargent A, ElSahwi K, Silasi DA, Azodi M. Vaginal Cuff Dehiscence in Robotic-Assisted Total Hysterectomy. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2012, 16: 530-536. PMID: 23484559, PMCID: PMC3558887, DOI: 10.4293/108680812x13462882736817.
- Gallo T, Kashani S, Patel DA, Elsahwi K, Silasi DA, Azodi M. Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2012, 16: 421-427. PMID: 23318068, PMCID: PMC3535794, DOI: 10.4293/108680812x13462882735890.
- Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal Of Experimental & Clinical Cancer Research 2011, 30: 106. PMID: 22075385, PMCID: PMC3224774, DOI: 10.1186/1756-9966-30-106.
- ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, Santin AD, Schwartz PE, Rutherford TJ, Azodi M. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecologic Oncology 2011, 124: 260-264. PMID: 22036203, DOI: 10.1016/j.ygyno.2011.09.038.
- El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study. Gynecologic Oncology 2011, 124: 471-473. PMID: 22014628, DOI: 10.1016/j.ygyno.2011.09.029.
- ElSahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ. The significance of perineural invasion in early-stage cervical cancer. Gynecologic Oncology 2011, 123: 561-564. PMID: 21968340, DOI: 10.1016/j.ygyno.2011.08.028.
- Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.
- Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prevention Research (Philadelphia, Pa.) 2011, 4: 1401-8. PMID: 21893500, PMCID: PMC3172691, DOI: 10.1158/1940-6207.CAPR-10-0402.
- Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American Journal Of Obstetrics And Gynecology 2011, 205: 567.e1-567.e7. PMID: 21889762, PMCID: PMC3224189, DOI: 10.1016/j.ajog.2011.06.093.
- Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clinical & Experimental Metastasis 2011, 28: 689-700. PMID: 21725665, PMCID: PMC3697933, DOI: 10.1007/s10585-011-9401-0.
- Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD. Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor. BMC Cancer 2011, 11: 263. PMID: 21693061, PMCID: PMC3141777, DOI: 10.1186/1471-2407-11-263.
- Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin‐Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117: 5519-5528. PMID: 21692061, PMCID: PMC3701957, DOI: 10.1002/cncr.26215.
- Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ. Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers. International Journal Of Gynecological Cancer 2011, 21: 633-639. PMID: 21412168, DOI: 10.1097/igc.0b013e3182126f05.
- Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody. International Journal Of Gynecological Cancer 2010, 20: 1440-1447. PMID: 21370592, PMCID: PMC3701951, DOI: 10.1111/igc.0b013e3181fb18a1.
- Toy EP, Lamb T, Azodi M, Roy WJ, Woo HH, Chambers SK. Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells. Breast Cancer Research And Treatment 2010, 129: 411-419. PMID: 21063905, DOI: 10.1007/s10549-010-1247-7.
- Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal Of Obstetrics And Gynecology 2010, 203: 582.e1-582.e7. PMID: 20870202, PMCID: PMC2993821, DOI: 10.1016/j.ajog.2010.07.041.
- Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal Of Cancer 2010, 103: 812-819. PMID: 20700124, PMCID: PMC2966612, DOI: 10.1038/sj.bjc.6605760.
- Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.
- El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201). Molecular Cancer Therapeutics 2010, 9: 57-66. PMID: 20053761, PMCID: PMC2806489, DOI: 10.1158/1535-7163.mct-09-0675.
- El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal Of Cancer 2009, 102: 134-143. PMID: 19920829, PMCID: PMC2813756, DOI: 10.1038/sj.bjc.6605448.
- Ratner ES, Toy E, O'Malley DM, Mcalpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE. Brain Metastases in Epithelial Ovarian and Primary Peritoneal Carcinoma. International Journal Of Gynecological Cancer 2009, 19: 856-859. PMID: 19574773, DOI: 10.1111/igc.0b013e3181a83301.
- Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.
- Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.
- Richter CE, Qian B, Martel M, Yu H, Azodi M, Rutherford TJ, Schwartz PE. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecologic Oncology 2009, 114: 99-104. PMID: 19410280, DOI: 10.1016/j.ygyno.2009.03.032.
- Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. Journal Of Virology 2009, 83: 6779-6789. PMID: 19386711, PMCID: PMC2698533, DOI: 10.1128/jvi.02443-08.
- Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK. Enhanced Ovarian Cancer Tumorigenesis and Metastasis by the Macrophage Colony-Stimulating Factor. Neoplasia 2009, 11: 136-144. PMID: 19177198, PMCID: PMC2631138, DOI: 10.1593/neo.81150.
- Tan O, Luchansky E, Rosenman S, Pua T, Azodi M. Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report. Archives Of Gynecology And Obstetrics 2009, 280: 333-335. PMID: 19184073, DOI: 10.1007/s00404-009-0946-y.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer. Cancer 2008, 115: 800-811. PMID: 19117353, DOI: 10.1002/cncr.24048.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2008, 200: 75.e1-75.e10. PMID: 18976739, DOI: 10.1016/j.ajog.2008.08.014.
- Abidi A, Menn K, Sherman A, Konia T, Azodi M. Cervical carcinosarcoma: a case report. The Journal Of Reproductive Medicine 2008, 53: 138-40. PMID: 18357808.
- SILASI D, ILLUZZI JL, KELLY MG, RUTHERFORD TJ, MOR G, AZODI M, SCHWARTZ PE. Carcinosarcoma of the ovary. International Journal Of Gynecological Cancer 2007, 18: 22-29. PMID: 17451459, DOI: 10.1111/j.1525-1438.2007.00948.x.
- Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecologic Oncology 2007, 105: 211-217. PMID: 17239941, DOI: 10.1016/j.ygyno.2006.11.025.
- Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. The Yale Journal Of Biology And Medicine 2006, 79: 153-63. PMID: 17940625, PMCID: PMC1994803.
- Mcalpine J, Hodgson E, Richman S, Zelterman D, Su Y, Abramovitz S, Kelly M, Azodi M, Rutherford T, Schwartz P. 0692: The Incidence of Postoperative Delirium in Geriatric Patients Undergoing Surgery for Suspected Gynecologic Malignancies. International Journal Of Gynecological Cancer 2006, 16: 794.2-794. DOI: 10.1136/ijgc-00009577-200610001-00692.
- McAlpine JN, Kelly MG, O'Malley DM, Azodi M, Coombe K, Schwartz PE, Rutherford TJ. Atypical presentations of carboplatin hypersensitivity reactions: Characterization and management in patients with gynecologic malignancies. Gynecologic Oncology 2006, 103: 288-292. PMID: 16647749, DOI: 10.1016/j.ygyno.2006.03.007.
- Koyfman SA, Abidi A, Ravichandran P, Higgins SA, Azodi M. Adenoid cystic carcinoma of the cervix. Gynecologic Oncology 2005, 99: 477-480. PMID: 16139349, DOI: 10.1016/j.ygyno.2005.06.063.
- Kelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology 2005, 98: 353-359. PMID: 16005947, DOI: 10.1016/j.ygyno.2005.06.012.
- O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2005, 98: 242-248. PMID: 15992916, DOI: 10.1016/j.ygyno.2005.04.032.
- Bonafé N, Gilmore-Hebert M, Folk NL, Azodi M, Zhou Y, Chambers SK. Glyceraldehyde-3-Phosphate Dehydrogenase Binds to the AU-Rich 3′ Untranslated Region of Colony-Stimulating Factor–1 (CSF-1) Messenger RNA in Human Ovarian Cancer Cells: Possible Role in CSF-1 Posttranscriptional Regulation and Tumor Phenotype. Cancer Research 2005, 65: 3762-3771. PMID: 15867372, DOI: 10.1158/0008-5472.can-04-3954.
- Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecologic Oncology 2004, 95: 469-473. PMID: 15581948, DOI: 10.1016/j.ygyno.2004.08.030.
Locations
1
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, suite B
New Haven, CT 06511
1 of 3
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecologic OncologyPark Avenue Medical Center5520 Park Avenue, Ste 1-500Trumbull, CT 06611
Biography
Masoud Azodi, MD, is the director of minimally invasive and robotic surgery for Yale Medicine obstetrics, gynecology and reproductive sciences. He has a special interest in using minimally invasive surgical techniques, particularly robotic surgery to treat patients with gynecologic precancers and cancers. Dr. Azodi has been a gynecologist at Yale for more than 20 years, performing more than 3,000 conventional laparoscopic and more than 3,000 robotic-assisted surgeries for management of gynecologic diseases.
“We provide excellent patient care, and our team works with the most up-to-date surgical techniques and research,” he says. Dr. Azodi has been recognized as one of the Top Doctors in the state by Castle Connolly Medical Ltd.
In addition to practicing surgery, Dr. Azodi is a principal investigator and co-principal investigator in multiple protocols treating gynecologic cancer. He is a professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine.
Titles
- Professor of Obstetrics, Gynecology and Reproductive Sciences
- Director of Minimally Invasive and Robotic Surgery, Director of Minimally Invasive Gynecologic Surgery Fellowship
Education & Training
- FellowshipYale University School of Medicine (1999)
- ResidencyAultman Hospital/Neoucom (1996)
- MDWright State University (1992)
Languages Spoken
- English
- فارسی (Persian)
Additional Information
Board Certifications
- AB of Obstetrics & Gynecology, Gynecologic Oncology (2002, recertified: 2022)
- AB of Obstetrics & Gynecology, Obstetrics & Gynecology (2000, recertified: 2022)
Publications
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.
- Khadraoui W, Tierney C, Chung S, Mutlu L, Lu L, Azodi M, Ratner E, Menderes G. Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer. International Journal Of Gynecology & Obstetrics 2020, 150: 385-391. PMID: 32506422, DOI: 10.1002/ijgo.13254.
- Bonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.
- Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers In Oncology 2020, 10: 118. PMID: 32117765, PMCID: PMC7028697, DOI: 10.3389/fonc.2020.00118.
- Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 2020, 11: 560-570. PMID: 32082489, PMCID: PMC7007291, DOI: 10.18632/oncotarget.27342.
- Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.
- Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.
- Benabou K, Kim S, Tierney CH, Messom JE, Kyriakides TC, Kashani SM, Silasi DA, Azodi M, Seifi F. Laparoscopic Posterior Versus Lateral Transversus Abdominis Plane Block in Gynecology. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2020, 24: e2020.00032. PMID: 32831540, PMCID: PMC7434395, DOI: 10.4293/jsls.2020.00032.
- Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.
- Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
- Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology 2019, 155: 144-150. PMID: 31434613, PMCID: PMC6788971, DOI: 10.1016/j.ygyno.2019.08.010.
- Kim S, Chung S, Azodi M, Menderes G. Uterine Artery–sparing Minimally Invasive Radical Trachelectomy: A Case Report and Review of the Literature. Journal Of Minimally Invasive Gynecology 2019, 26: 1389-1395. PMID: 31173940, DOI: 10.1016/j.jmig.2019.05.017.
- Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.
- Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology 2019, 20: 636-648. PMID: 30948273, DOI: 10.1016/s1470-2045(19)30029-4.
- Azodi M, Hesson D. Robotic Surgery: Research and Reviews is indexed in PubMed. Robotic Surgery Research And Reviews 2019, 6: 1-2. PMID: 30989084, PMCID: PMC6440532, DOI: 10.2147/rsrr.s204381.
- Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.
- Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.
- Tierney C, Chung SH, Feinberg J, Haines K, Yadav G, Azodi M, Menderes G. A Novel Approach to Combined Vaginal and Laparoscopic Gynecological Surgery. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: ejsls.2019.00006. PMID: 31097905, PMCID: PMC6464071, DOI: 10.4293/jsls.2019.00006.
- Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
- Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Menderes G, Leon-Martinez D, Azodi M. Laparoscopic Ligation of Uterine Vasculature for Fertility-Sparing Management of Postabortal Hemorrhage. Journal Of Minimally Invasive Gynecology 2018, 26: 36-37. PMID: 29609031, DOI: 10.1016/j.jmig.2018.03.020.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal Of Clinical Oncology 2018, 36: 2044-2051. PMID: 29584549, DOI: 10.1200/jco.2017.76.5966.
- Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.
- Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Gynecologic Oncology Reports 2018, 23: 28-33. PMID: 29387776, PMCID: PMC5771964, DOI: 10.1016/j.gore.2018.01.003.
- Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research 2017, 23: 5836-5845. PMID: 28679774, PMCID: PMC5626613, DOI: 10.1158/1078-0432.ccr-16-2862.
- Kim S, Hill A, Menderes G, Cross S, Azodi M, Bahtiyar MO. Minimally invasive abdominal cerclage compared to laparotomy: a comparison of surgical and obstetric outcomes. Journal Of Robotic Surgery 2017, 12: 295-301. PMID: 28721634, DOI: 10.1007/s11701-017-0726-9.
- Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.
- Menderes G, Dugan K, Klein MJ, Azodi M. Natural Orifice–Assisted Laparoscopic Meckel Diverticulectomy Incidentally Found During Para-Aortic Mass Resection. Journal Of Minimally Invasive Gynecology 2017, 25: 19-20. PMID: 28478192, DOI: 10.1016/j.jmig.2017.04.015.
- Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.
- Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology 2017, 34: 91. PMID: 28397106, PMCID: PMC5896014, DOI: 10.1007/s12032-017-0956-8.
- Deshmukh U, McAdow M, Black J, Hui P, Azodi M. Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. Gynecologic Oncology Reports 2017, 20: 54-57. PMID: 28331901, PMCID: PMC5348602, DOI: 10.1016/j.gore.2017.03.001.
- Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
- Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.
- Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.
- Hill AM, Davis KM, Clark-Donat L, Hammons LM, Azodi M, Silasi DA. The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2016, 24: 108-113. PMID: 27702701, DOI: 10.1016/j.jmig.2016.09.015.
- Gojayev A, English DP, Macer M, Azodi M. Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer. Case Reports In Obstetrics And Gynecology 2016, 2016: 8547173. PMID: 27747116, PMCID: PMC5055912, DOI: 10.1155/2016/8547173.
- Menderes G, Black JD, Azodi M. The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer. Expert Review Of Anticancer Therapy 2016, 16: 899-901. PMID: 27477495, DOI: 10.1080/14737140.2016.1219658.
- Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.
- Stahl JM, Park HS, Silasi DA, Azodi M, Damast S. Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients. Practical Radiation Oncology 2016, 6: 226-232. PMID: 27364883, DOI: 10.1016/j.prro.2015.09.015.
- Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.
- Menderes G, Vilardo N, Schwab CL, Azodi M. Incidental injury and repair of obturator nerve during laparoscopic pelvic lymphadenectomy. Gynecologic Oncology 2016, 142: 208. PMID: 27234143, DOI: 10.1016/j.ygyno.2016.05.023.
- Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.
- Zeybek B, Hill A, Menderes G, Borahay MA, Azodi M, Kilic GS. Robot-Assisted Abdominal Cerclage During Pregnancy. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2016, 20: e2016.00072. PMID: 27904309, PMCID: PMC5118107, DOI: 10.4293/jsls.2016.00072.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1641-1641. PMID: 26625219, PMCID: PMC4705897, DOI: 10.1038/bjc.2015.388.
- Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics 2015, 14: 2519-2526. PMID: 26333383, PMCID: PMC4636465, DOI: 10.1158/1535-7163.mct-15-0383.
- Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.
- Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal Of Experimental & Clinical Cancer Research 2015, 34: 123. PMID: 26474755, PMCID: PMC4609066, DOI: 10.1186/s13046-015-0241-7.
- Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA. Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? Journal Of Minimally Invasive Gynecology 2015, 22: s48-s49. PMID: 27679256, DOI: 10.1016/j.jmig.2015.08.134.
- Tower AM, Clark Donat L, Azodi M, Silasi DA. The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2015, 22: s77. PMID: 27679335, DOI: 10.1016/j.jmig.2015.08.205.
- Clark Donat L, Tower A, Clark M, Silasi DA, Azodi M. Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma. Journal Of Minimally Invasive Gynecology 2015, 22: s59. PMID: 27679285, DOI: 10.1016/j.jmig.2015.08.157.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1020-1026. PMID: 26325104, PMCID: PMC4651122, DOI: 10.1038/bjc.2015.306.
- Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer. International Journal Of Cancer 2015, 137: 2618-2629. PMID: 26060989, PMCID: PMC4573336, DOI: 10.1002/ijc.29632.
- Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.
- Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 112-117. PMID: 26260909, PMCID: PMC4587290, DOI: 10.1016/j.ygyno.2015.08.002.
- Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.
- Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology 2015, 138: 11-17. PMID: 25931171, PMCID: PMC4469551, DOI: 10.1016/j.ygyno.2015.04.027.
- Menderes G, Clark M, Tower A, Azodi M. External Iliac Vein Injury and Repair During Robotic-assisted Pelvic Lymphadenectomy. Journal Of Minimally Invasive Gynecology 2015, 22: 718. PMID: 25888352, DOI: 10.1016/j.jmig.2015.04.007.
- English D, Menderes G, Azodi M. Controlled removal of a large uterus within a bowel bag and morcellation in the bowel bag from the vagina. Gynecologic Oncology 2015, 137: 589-590. PMID: 25797081, DOI: 10.1016/j.ygyno.2015.03.014.
- Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.
- Menderes G, Clark M, Clark-Donat L, Azodi M. Robotic-assisted Abdominal Cerclage Placement During Pregnancy and Its Challenges. Journal Of Minimally Invasive Gynecology 2015, 22: 713-714. PMID: 25772022, DOI: 10.1016/j.jmig.2015.03.006.
- Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology 2015, 36: 5505-5513. PMID: 25669172, PMCID: PMC5573583, DOI: 10.1007/s13277-015-3218-4.
- Donat LC, Menderes G, Tower AM, Azodi M. A Technique for Vascular Control During Robotic-assisted Laparoscopic Myomectomy. Journal Of Minimally Invasive Gynecology 2015, 22: 543. PMID: 25680685, DOI: 10.1016/j.jmig.2015.02.003.
- Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors. Cancer 2015, 121: 1817-1826. PMID: 25649370, DOI: 10.1002/cncr.29254.
- Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.
- Clark LE, Menderes G, Tower AM, Silasi DA, Azodi M. A Simple Approach to Specimen Retrieval via Posterior Colpotomy Incision. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2015, 19: e2015.00222. PMID: 25901107, PMCID: PMC4396057, DOI: 10.4293/jsls.2014.00222.
- Menderes G, Azodi M, Schwartz P, Silasi DA. Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging. International Journal Of Gynecological Cancer 2015, 25: 160-165. PMID: 25386859, DOI: 10.1097/igc.0000000000000308.
- Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics. International Journal Of Gynecological Cancer 2014, 25: 431. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/igc.0000000000000376.
- Menderes G, Clark LE, Azodi M. Needleless Laparoscopic Abdominal Cerclage Placement. Journal Of Minimally Invasive Gynecology 2014, 22: 321. PMID: 25489676, DOI: 10.1016/j.jmig.2014.11.011.
- Menderes G, Clark LE, Azodi M. Incidental Ureteral Injury and Repair during Robotic-assisted Total Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2014, 22: 320. PMID: 25461686, DOI: 10.1016/j.jmig.2014.11.006.
- Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal Of Cancer 2014, 111: 1750-1756. PMID: 25268372, PMCID: PMC4453741, DOI: 10.1038/bjc.2014.519.
- English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2014, 121: 403-412. PMID: 25251053, PMCID: PMC4304922, DOI: 10.1002/cncr.29062.
- Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical EvidenceGruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK. Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence. Cancer Prevention Research 2014, 7: 896-905. PMID: 24950779, PMCID: PMC4154987, DOI: 10.1158/1940-6207.capr-13-0408.
- Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.
- Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.
- Pasternak MC, Black JD, Buza N, Azodi M, Gariepy A. An unexpected mass of the urachus: a case report. American Journal Of Obstetrics And Gynecology 2014, 211: e1-e3. PMID: 24912094, DOI: 10.1016/j.ajog.2014.06.011.
- English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine 2014, 3: 1256-1265. PMID: 24890382, PMCID: PMC4302675, DOI: 10.1002/cam4.274.
- Menderes G, Clark L, Azodi M. Robotic-assisted abdominal cerclage: a case report and literature review. Journal Of Robotic Surgery 2014, 8: 195-200. PMID: 27637677, DOI: 10.1007/s11701-014-0462-3.
- Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.
- Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.
- Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, Mor G. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine 2013, 2: 751-762. PMID: 24403249, PMCID: PMC3892380, DOI: 10.1002/cam4.115.
- Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British Journal Of Cancer 2013, 109: 462-471. PMID: 23807163, PMCID: PMC3721400, DOI: 10.1038/bjc.2013.315.
- Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119: 2582-2592. PMID: 23585021, PMCID: PMC3700638, DOI: 10.1002/cncr.28017.
- Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 2916-2921. PMID: 23359684, PMCID: PMC3581983, DOI: 10.1073/pnas.1222577110.
- La Rosa MF, McCarthy S, Richter C, Azodi M. Robotic Repair of Uterine Dehiscence. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2013, 17: 156-160. PMID: 23743391, PMCID: PMC3662738, DOI: 10.4293/108680812x13517013317996.
- Silasi DA, Gallo T, Silasi M, Menderes G, Azodi M. Robotic Versus Abdominal Hysterectomy for Very Large Uteri. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2013, 17: 400-406. PMID: 24018076, PMCID: PMC3771758, DOI: 10.4293/108680813x13693422521755.
- Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal Of Surgical Oncology 2012, 107: 195-200. PMID: 22648987, DOI: 10.1002/jso.23171.
- Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal Of Cancer 2012, 106: 1543-1550. PMID: 22531721, PMCID: PMC3341945, DOI: 10.1038/bjc.2012.132.
- Kashani S, Gallo T, Sargent A, ElSahwi K, Silasi DA, Azodi M. Vaginal Cuff Dehiscence in Robotic-Assisted Total Hysterectomy. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2012, 16: 530-536. PMID: 23484559, PMCID: PMC3558887, DOI: 10.4293/108680812x13462882736817.
- Gallo T, Kashani S, Patel DA, Elsahwi K, Silasi DA, Azodi M. Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2012, 16: 421-427. PMID: 23318068, PMCID: PMC3535794, DOI: 10.4293/108680812x13462882735890.
- Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal Of Experimental & Clinical Cancer Research 2011, 30: 106. PMID: 22075385, PMCID: PMC3224774, DOI: 10.1186/1756-9966-30-106.
- ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, Santin AD, Schwartz PE, Rutherford TJ, Azodi M. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecologic Oncology 2011, 124: 260-264. PMID: 22036203, DOI: 10.1016/j.ygyno.2011.09.038.
- El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study. Gynecologic Oncology 2011, 124: 471-473. PMID: 22014628, DOI: 10.1016/j.ygyno.2011.09.029.
- ElSahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ. The significance of perineural invasion in early-stage cervical cancer. Gynecologic Oncology 2011, 123: 561-564. PMID: 21968340, DOI: 10.1016/j.ygyno.2011.08.028.
- Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.
- Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prevention Research (Philadelphia, Pa.) 2011, 4: 1401-8. PMID: 21893500, PMCID: PMC3172691, DOI: 10.1158/1940-6207.CAPR-10-0402.
- Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American Journal Of Obstetrics And Gynecology 2011, 205: 567.e1-567.e7. PMID: 21889762, PMCID: PMC3224189, DOI: 10.1016/j.ajog.2011.06.093.
- Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clinical & Experimental Metastasis 2011, 28: 689-700. PMID: 21725665, PMCID: PMC3697933, DOI: 10.1007/s10585-011-9401-0.
- Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD. Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor. BMC Cancer 2011, 11: 263. PMID: 21693061, PMCID: PMC3141777, DOI: 10.1186/1471-2407-11-263.
- Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin‐Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117: 5519-5528. PMID: 21692061, PMCID: PMC3701957, DOI: 10.1002/cncr.26215.
- Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ. Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers. International Journal Of Gynecological Cancer 2011, 21: 633-639. PMID: 21412168, DOI: 10.1097/igc.0b013e3182126f05.
- Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody. International Journal Of Gynecological Cancer 2010, 20: 1440-1447. PMID: 21370592, PMCID: PMC3701951, DOI: 10.1111/igc.0b013e3181fb18a1.
- Toy EP, Lamb T, Azodi M, Roy WJ, Woo HH, Chambers SK. Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells. Breast Cancer Research And Treatment 2010, 129: 411-419. PMID: 21063905, DOI: 10.1007/s10549-010-1247-7.
- Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal Of Obstetrics And Gynecology 2010, 203: 582.e1-582.e7. PMID: 20870202, PMCID: PMC2993821, DOI: 10.1016/j.ajog.2010.07.041.
- Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal Of Cancer 2010, 103: 812-819. PMID: 20700124, PMCID: PMC2966612, DOI: 10.1038/sj.bjc.6605760.
- Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.
- El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201). Molecular Cancer Therapeutics 2010, 9: 57-66. PMID: 20053761, PMCID: PMC2806489, DOI: 10.1158/1535-7163.mct-09-0675.
- El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal Of Cancer 2009, 102: 134-143. PMID: 19920829, PMCID: PMC2813756, DOI: 10.1038/sj.bjc.6605448.
- Ratner ES, Toy E, O'Malley DM, Mcalpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE. Brain Metastases in Epithelial Ovarian and Primary Peritoneal Carcinoma. International Journal Of Gynecological Cancer 2009, 19: 856-859. PMID: 19574773, DOI: 10.1111/igc.0b013e3181a83301.
- Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.
- Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.
- Richter CE, Qian B, Martel M, Yu H, Azodi M, Rutherford TJ, Schwartz PE. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecologic Oncology 2009, 114: 99-104. PMID: 19410280, DOI: 10.1016/j.ygyno.2009.03.032.
- Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. Journal Of Virology 2009, 83: 6779-6789. PMID: 19386711, PMCID: PMC2698533, DOI: 10.1128/jvi.02443-08.
- Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK. Enhanced Ovarian Cancer Tumorigenesis and Metastasis by the Macrophage Colony-Stimulating Factor. Neoplasia 2009, 11: 136-144. PMID: 19177198, PMCID: PMC2631138, DOI: 10.1593/neo.81150.
- Tan O, Luchansky E, Rosenman S, Pua T, Azodi M. Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report. Archives Of Gynecology And Obstetrics 2009, 280: 333-335. PMID: 19184073, DOI: 10.1007/s00404-009-0946-y.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer. Cancer 2008, 115: 800-811. PMID: 19117353, DOI: 10.1002/cncr.24048.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2008, 200: 75.e1-75.e10. PMID: 18976739, DOI: 10.1016/j.ajog.2008.08.014.
- Abidi A, Menn K, Sherman A, Konia T, Azodi M. Cervical carcinosarcoma: a case report. The Journal Of Reproductive Medicine 2008, 53: 138-40. PMID: 18357808.
- SILASI D, ILLUZZI JL, KELLY MG, RUTHERFORD TJ, MOR G, AZODI M, SCHWARTZ PE. Carcinosarcoma of the ovary. International Journal Of Gynecological Cancer 2007, 18: 22-29. PMID: 17451459, DOI: 10.1111/j.1525-1438.2007.00948.x.
- Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecologic Oncology 2007, 105: 211-217. PMID: 17239941, DOI: 10.1016/j.ygyno.2006.11.025.
- Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. The Yale Journal Of Biology And Medicine 2006, 79: 153-63. PMID: 17940625, PMCID: PMC1994803.
- Mcalpine J, Hodgson E, Richman S, Zelterman D, Su Y, Abramovitz S, Kelly M, Azodi M, Rutherford T, Schwartz P. 0692: The Incidence of Postoperative Delirium in Geriatric Patients Undergoing Surgery for Suspected Gynecologic Malignancies. International Journal Of Gynecological Cancer 2006, 16: 794.2-794. DOI: 10.1136/ijgc-00009577-200610001-00692.
- McAlpine JN, Kelly MG, O'Malley DM, Azodi M, Coombe K, Schwartz PE, Rutherford TJ. Atypical presentations of carboplatin hypersensitivity reactions: Characterization and management in patients with gynecologic malignancies. Gynecologic Oncology 2006, 103: 288-292. PMID: 16647749, DOI: 10.1016/j.ygyno.2006.03.007.
- Koyfman SA, Abidi A, Ravichandran P, Higgins SA, Azodi M. Adenoid cystic carcinoma of the cervix. Gynecologic Oncology 2005, 99: 477-480. PMID: 16139349, DOI: 10.1016/j.ygyno.2005.06.063.
- Kelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology 2005, 98: 353-359. PMID: 16005947, DOI: 10.1016/j.ygyno.2005.06.012.
- O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2005, 98: 242-248. PMID: 15992916, DOI: 10.1016/j.ygyno.2005.04.032.
- Bonafé N, Gilmore-Hebert M, Folk NL, Azodi M, Zhou Y, Chambers SK. Glyceraldehyde-3-Phosphate Dehydrogenase Binds to the AU-Rich 3′ Untranslated Region of Colony-Stimulating Factor–1 (CSF-1) Messenger RNA in Human Ovarian Cancer Cells: Possible Role in CSF-1 Posttranscriptional Regulation and Tumor Phenotype. Cancer Research 2005, 65: 3762-3771. PMID: 15867372, DOI: 10.1158/0008-5472.can-04-3954.
- Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecologic Oncology 2004, 95: 469-473. PMID: 15581948, DOI: 10.1016/j.ygyno.2004.08.030.
Locations
1
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, suite B
New Haven, CT 06511
1 of 3
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecologic OncologyPark Avenue Medical Center5520 Park Avenue, Ste 1-500Trumbull, CT 06611
1
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, suite B
New Haven, CT 06511
1 of 3
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecologic OncologyPark Avenue Medical Center5520 Park Avenue, Ste 1-500Trumbull, CT 06611